An FDA Form 483 is a document that FDA investigators hand to a company at the end of an inspection, listing conditions or practices they observed that may violate federal regulations. It is not a fine, a citation, or a final legal judgment. It’s a formal notice that the agency found problems worth documenting, and it signals that the company needs to act quickly to address them.
What a 483 Actually Says
The form itself is straightforward. Each item on it is called an “observation,” and each observation describes a specific condition the investigator witnessed, reviewed in records, or otherwise documented during the inspection. These might involve anything from contamination risks in a manufacturing area to incomplete recordkeeping to failures in quality control testing.
A critical point: a 483 does not constitute a final agency determination that a violation has occurred. The FDA treats it as one piece of a larger puzzle. After the inspection, the agency reviews the 483 alongside a more detailed internal document called an Establishment Inspection Report, all evidence collected on-site, and any response the company submits. Only after weighing all of that does the FDA decide whether further enforcement action is warranted.
How Common Are 483s?
Not every inspection results in a 483. In fiscal year 2024, the FDA conducted 692 clinical investigator inspections. Of those, 536 (77%) ended with no Form 483 issued. Only 156 inspections (23%) resulted in one. So receiving a 483 is not automatic, but it’s not rare either. The percentage varies across different types of facilities and industries the FDA regulates, including drug manufacturers, food processors, medical device companies, and clinical trial sites.
What Inspectors Most Often Flag
The specific observations on a 483 depend on the type of facility, but certain themes come up repeatedly. In clinical investigation inspections during fiscal year 2024, the most common observations involved failure to follow study protocols, inadequate or inaccurate case histories, failure to promptly report adverse events to the study sponsor, poor accountability records for investigational products, and issues with institutional review board oversight.
For drug manufacturing facilities, common observations tend to center on equipment cleaning, laboratory controls, documentation gaps, and failures in procedures designed to prevent contamination or mix-ups. The throughline across industries is the same: the FDA looks for gaps between what a company’s written procedures require and what actually happens on the ground.
The 15-Business-Day Response Window
Responding to a 483 is technically voluntary, but ignoring one is risky. The FDA recommends that companies submit a written response within 15 business days of the form being issued. Business days are counted Monday through Friday, excluding federal holidays. That 15-day window matters because the FDA has stated it will not ordinarily delay regulatory action, such as issuing a warning letter, to wait for a response that arrives after that deadline.
For complex observations that can’t be fully resolved in 15 days, the FDA recommends companies submit a corrective action plan with a proposed timeline for completing each fix. The goal is to show the agency that the company takes the findings seriously and has a concrete strategy for addressing them, even if the full remediation will take weeks or months.
What Happens After a 483
The 483 kicks off a review process inside the FDA. An endorsing office reviews the inspection report, the on-site evidence, and the company’s response (if one was submitted) to assign a final classification to the inspection. That classification determines what happens next.
If the agency is satisfied that the company has corrected or is credibly correcting the issues, the matter may be closed with no further action. If the problems are serious or the response is inadequate, the FDA can escalate. The next step up is typically a warning letter, which is a more formal notice that the agency considers the violations significant. Beyond that, the FDA has tools ranging from import alerts (blocking products from entering the U.S.) to consent decrees, seizures, and injunctions that can shut down production entirely. In extreme cases, criminal prosecution is possible.
For companies with pending product applications, unresolved 483 observations at a manufacturing facility can delay or block approvals. The FDA may decline to approve a new drug or device if the facility where it would be made has outstanding quality concerns.
483s Are Public Records
Form 483s are not confidential. The FDA’s Office of Inspections and Investigations maintains an electronic reading room where select inspection records, including 483s, are posted publicly. Some are released proactively by the agency, while others become available because they’ve been frequently requested under the Freedom of Information Act. If a specific 483 isn’t already posted, anyone can request it through a FOIA submission.
This public visibility adds a reputational dimension. Investors, competitors, customers, and journalists can all access these documents. For publicly traded pharmaceutical or medical device companies, a 483 with serious observations can move stock prices and trigger questions from analysts. Even for smaller companies, having quality problems on the public record can affect partnerships and contracts.
How Companies Typically Respond
A strong 483 response addresses each observation individually. For every item, the company identifies what went wrong (root cause analysis), what immediate corrections were made, and what longer-term changes to procedures, training, or equipment will prevent the issue from recurring. This structured approach is often called a corrective and preventive action plan, or CAPA.
The most effective responses include evidence: photos of repaired equipment, revised standard operating procedures with tracked changes, training records showing staff have been retrained, or data from follow-up testing. Vague promises to “look into” an issue are far less persuasive to FDA reviewers than documentation showing concrete steps already taken. Companies that treat the 483 as a starting point for genuine quality improvement, rather than a paperwork exercise, tend to fare better in the agency’s final assessment.